Providence published findings today demonstrating appreciable declines in unplanned hospitalizations along with an increase in hospital mortality for a broad mix of medical conditions during the COVID-19 pandemic.
Biological E has entered into an agreement with Canada-based Providence Therapeutics Holdings, to manufacture the latter’s mRNA (messenger Ribonucleic acid) vaccine PTX-COVID19-B in India.